Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma"

Cancers

Volumn 5, Issue 1, 2013, Pages 218-233

  Kelleher, Fergal C ^a,b   Viterbo, Antonella ^b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gene expression arrays; Lineage differentiation; Malignant fibrous histiocytoma; Undifferentiated pleomorphic sarcoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; NERVE GROWTH FACTOR BETA SUBUNIT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN C;

CANCER CLASSIFICATION; CANCER LOCALIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; FIBROBLAST GROWTH FACTOR RECEPTOR GENE; FIBROSARCOMA; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MESENCHYMAL STEM CELL; MULTIPLE CANCER; NERVE GROWTH FACTOR BETA SUBUNIT GENE; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; REVIEW; SARCOMA; SOMATOMEDIN C GENE; TUMOR DIFFERENTIATION; TUMOR GENE; ULTRASTRUCTURE; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

EID: 84875254528     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5010218     Document Type: Review

References (50)

1. Crozat, A.; Aman, P.; Mandahl, N.; Ron, D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363, 640-644.
2. Clark, J.; Rocques, P.J.; Crew, A.J.; Gill, S.; Shipley, J.; Chan, A.M.; Gusterson, B.A. Cooper CSIdentification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 1994, 7, 502-508.
3. Quesada, J.; Amato, R. The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma 2012, 2012, 849456.
4. Dunham, M.A.; Neumann, A.A.; Fasching, C.L.; Reddel, R.R. Telomere maintenance by recombination in human cells. Nat. Genet. 2000, 26, 447-450.
5. Ulaner, G.A.; Hoffman, A.R.; Otero, J.; Huang, H.Y.; Zhao, Z.; Mazumdar, M.; Gorlick, R.; Meyers, P.; Healey, J.H.; Ladanyi, M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004, 41, 155-162.
6. Scheel, C.; Schaefer, K.L.; Jauch, A.; Keller, M.; Wai, D.; Brinkschmidt, C.; van Valen, F.; Boecker, W.; Dockhorn-Dworniczak, B.; Poremba, C. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001, 20, 3835-3844.
7. Nielsen, T.O.; West, R.B. Translating gene expression into clinical care: Sarcomas as a paradigm. J. Clin. Oncol. 2010, 28, 1796-1805.
8. Fletcher, C.D. Pleomorphic malignant fibrous histiocytoma: Fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am. J. Surg. Pathol. 1992, 16, 213-228
9. Fletcher, C.D.; Gustafson, P.; Rydholm, A.; Willén, H.; Akerman, M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of subclassification. J. Clin. Oncol. 2001, 19, 3045-3050.
10. Mentzel, T.; Calonje, E.; Wadden, C.; Camplejohn, R.S.; Beham, A.; Smith, M.A.; Fletcher, C.D. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am. J. Surg. Pathol. 1996, 20, 391-405.
11. McCormick, D.; Mentzel, T.; Beham, A.; Fletcher, C.D. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am. J. Surg. Pathol. 1994, 18, 1213-1223.
12. Henricks, W.H.; Chu, Y.C.; Goldblum, J.R.; Weiss, S.W. Dedifferentiated liposarcoma: A clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am. J. Surg. Pathol. 1997, 21, 271-281.
13. Merck, C.; Angervall, L.; Kindblom, L.G.; Odén, A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol. Microbiol. Immunol. Scand. Suppl. 1983, 282, 1-40.
14. Nielsen, T.O.; West, R.B.; Linn, S.C.; Alter, O.; Knowling, M.A.; O'Connell, J.X.; Zhu, S.; Fero, M.; Sherlock, G.; Pollack, J.R et al. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 2002, 359, 1301-1307.
15. Nakayama, R.; Nemoto, T.; Takahashi, H.; Ohta, T.; Kawai, A.; Seki, K.; Yoshida, T.; Toyama, Y.; Ichikawa, H.; Hasegawa, T. Gene expression analysis of soft tissue sarcomas: Characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol. 2007, 20, 749-759.
16. Obermann, H.; Samalecos, A.; Osterhoff, C.; Schröder, B.; Heller, R.; Kirchhoff, C. HE6, a two-subunit heptahelical receptor associated with apical membranes of efferent and epididymal duct epithelia. Mol. Reprod. Dev. 2003, 64, 13-26.
17. Baird, K.; Davis, S.; Antonescu, C.R.; Harper, U.L.; Walker, R.L.; Chen, Y.; Glatfelter, A.A.; Duray, P.H.; Meltzer, P.S. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res. 2005, 65, 9226-9235.
18. Skubitz, K.M.; Francis, P.; Skubitz, A.P.; Luo, X.; Nilbert, M. Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas. Cancer 2012, 118, 4235-4243.
19. Stoeckle, E.; Coindre, J.M.; Bonvalot, S.; Kantor, G.; Terrier, P.; Bonichon, F.; Nguyen Bui, B.; French Federation of Cancer Centers Sarcoma Group. Prognostic factors in retroperitoneal sarcoma: A multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001, 92, 359-368.
20. Pinson, C.W.; ReMine, S.G.; Fletcher, W.S.; Braasch, J.W. Long-term results with primary retroperitoneal tumors. Arch. Surg. 1989, 124, 1168-1173.
21. Catton, C.N.; O'Sullivan, B.; Kotwall, C.; Cummings, B.; Hao, Y.; Fornasier, V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 1005-1010.
22. Kilkenny, J.W., 3rd; Bland, K.I.; Copeland, E.M., 3rd. Retroperitoneal sarcoma: The University of Florida experience. J. Am. Coll. Surg. 1996, 182, 329-339.
23. Karakousis, C.P.; Velez, A.F.; Gerstenbluth, R.; Driscoll, D.L. Resectability and survival in retroperitoneal sarcomas. Ann. Surg. Oncol. 1996, 3, 150-158.
24. Lewis, J.J.; Leung, D.; Woodruff, J.M.; Brennan, M.F. Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution. Ann. Surg. 1998, 228, 355-365.
25. Herman, K.; Gruchala, A.; Niezabitowski, A.; Gliński, B.; Lackowska, B. Prognostic factors in retroperitoneal sarcomas: Ploidy of DNA as a predictor of clinical outcome. J. Surg. Oncol. 1999, 71, 32-35.
26. Coindre, J.M.; Mariani, O.; Chibon, F.; Mairal, A.; de Saint Aubain Somerhausen, N.; Favre-Guillevin, E.; Bui, N.B.; Stoeckle, E.; Hostein, I.; Aurias, A. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: A review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod. Pathol. 2003, 16, 256-262.
27. Pilotti, S.; Della Torre, G.; Lavarino, C.; Sozzi, G.; Minoletti, F.; Vergani, B.; Azzarelli, A.; Rilke, F.; Pierotti, M.A. Molecular abnormalities in liposarcoma: Role of MDM2 and CDK4-containing amplicons at 12q13-22. J. Pathol. 1998, 185, 188-190.
28. Horvai, A.E.; Schaefer, J.T.; Nakakura, E.K.; O'Donnell, R.J. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod. Pathol. 2008, 21, 517-524.
29. Haun, J.B.; Castro, C.M.; Wang, R.; Peterson, V.M.; Marinelli, B.S.; Lee, H.; Weissleder, R. Micro-NMR for rapid molecular analysis of human tumor samples. Sci. Transl. Med. 2011, 3, 71ra16.
30. Tanas, M.R.; Sboner, A.; Oliveira, A.M.; Erickson-Johnson, M.R.; Hespelt, J.; Hanwright, P.J.; Flanagan, J.; Luo, Y.; Fenwick, K.; Natrajan, R, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 2011, 3, 98ra82.
31. Rodriguez, R.; Rubio, R.; Menendez, P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res. 2012, 22, 62-77.
32. Helman, L.J.; Meltzer, P. Mechanisms of sarcoma development. Nat. Rev. Cancer 2003, 3, 685-694.
33. Fodde, R.; Brabletz, T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19, 150-158.
34. Matushansky, I.; Hernando, E.; Socci, N.D.; Mills, J.E.; Matos, T.A.; Edgar, M.A.; Singer, S.; Maki, R.G.; Cordon-Cardo, C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 2007, 117, 3248-3257.
35. Fodde, R.; Brabletz, T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19, 150-158.
36. Matthay, K.K.; Villablanca, J.G.; Seeger, R.C.; Stram, D.O.; Harris, R.E.; Ramsay, N.K.; Swift, P.; Shimada, H.; Black, C.T.; Brodeur, G.M, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med. 1999, 341, 1165-1173.
37. Rodriguez, R.; Rubio, R.; Masip, M.; Catalina, P.; Nieto, A.; de la Cueva, T.; Arriero, M.; San Martin, N.; de la Cueva, E.; Balomenos, D, et al. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 2009, 11, 397-407.
38. Henderson, S.R.; Guiliano, D.; Presneau, N.; McLean, S.; Frow, R.; Vujovic, S.; Anderson, J.; Sebire, N.; Whelan, J.; Athanasou, N, et al. A molecular map of mesenchymal tumors. Genome Biol. 2005, 6, R76.
39. Detwiller, K.Y.; Fernando, N.T.; Segal, N.H.; Ryeom, S.W.; D'Amore, P.A.; Yoon, S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 2005, 65, 5881-5889.
40. Konstantinopoulos, P.A.; Fountzilas, E.; Goldsmith, J.D.; Bhasin, M.; Pillay, K.; Francoeur, N.; Libermann, T.A.; Gebhardt, M.C.; Spentzos, D. Analysis of multiple sarcoma expression datasets: Implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One 2010, 5, e9747.
41. Yuen, J.S.; Macaulay, V.M. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin. Ther. Targets 2008, 12, 589-603.
42. Blay, J.Y.; Ray-Coquard, I.; Alberti, L.; Ranchère, D. Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas. Cancer Treat. Res. 2004, 120, 151-167.
43. Adriaenssens, E.; Vanhecke, E.; Saule, P.; Mougel, A.; Page, A.; Romon, R.; Nurcombe, V.; Le Bourhis, X.; Hondermarck, H. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 2008, 68, 346-351.
44. Martnez-Torrecuadrada, J.; Cifuentes, G.; López-Serra, P.; Saenz, P.; Martnez, A.; Casal, J.I. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin. Cancer Res. 2005, 11, 6280-6290.
45. Mito, J.K.; Riedel, R.F.; Dodd, L.; Lahat, G.; Lazar, A.J.; Dodd, R.D.; Stangenberg, L.; Eward, W.C.; Hornicek, F.J.; Yoon, S.S.; et al. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One 2009, 4, e8075.
46. Kwong, L.N.; Costello, J.C.; Liu, H.; Jiang, S.; Helms, T.L.; Langsdorf, A.E.; Jakubosky, D.; Genovese, G.; Muller, F.L.; Jeong, J.H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 2012, 18, 1503-1510.
47. Honoki, K.; Fujii, H.; Tohma, Y.; Tsujiuchi, T.; Kido, A.; Tsukamoto, S.; Mori, T.; Tanaka, Y. Comparison of gene expression profiling in sarcomas and mesenchymal stem cells identifies tumorigenic pathways in chemically induced rat sarcoma model. ISRN Oncol. 2012, 2012, 909453.
48. Sekulic, A.; Migden, M.R.; Oro, A.E.; Dirix, L.; Lewis, K.D.; Hainsworth, J.D.; Solomon, J.A.; Yoo, S.; Arron, S.T.; Friedlander, P.A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 2012, 366, 2171-2179.
49. Fellner, C. Vismodegib (erivedge) for advanced Basal cell carcinoma. Pharm. Ther. 2012, 37, 670-682.
50. Lahat, G.; Zhang, P.; Zhu, Q.S.; Torres, K.; Ghadimi, M.; Smith, K.D.; Wang, W.L.; Lazar, A.J.; Lev, D. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): A tissue microarray study. Histopathology 2011, 59, 556-561.